You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The closing range uses available history since Jul 21, 2026; less than a full year is stored.
ARC Group Acquisition I Corp. received Nasdaq approval until February 23, 2027 to regain compliance with the continued listing rule requiring its outstanding warrants to maintain an aggregate market value of at least $1 million; failure could result in delisting.
Illustrative technical + ownership context — a signal mix, not investment advice.
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARCLW
this stock
ARC Group Acquisition I Corp.
|
$58.58M | — | — | — | — |
|
VYLR
Vylor Inc.
|
$45.73B | — | — | — | 2.2% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$651.01M | +3.2% | — | — | 0.0% |
|
CCXI
Churchill Capital Corp XI
|
$627.18M | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
ARC Group Acquisition I Corp. received Nasdaq approval until February 23, 2027 to regain compliance with the continued listing rule requiring its outstanding warrants to maintain an aggregate market value of at least $1 million; failure could result in delisting.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARCLW | -16.8% | — | — | -18.7% | — |
| SPY | -2.0% | -3.2% | +1.6% | -0.2% | +10.6% |
| vs SPY | -14.8% | — | — | -18.5% | — |
